Skip to main content

Advertisement

Volume 10 Supplement 1

de Senectute: Age and Health Forum

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)

Article metrics

  • 951 Accesses

Background

Vascular endothelial growth factor (VEGF) is considered to play an essential role in the pathogenesis of age-related macular degeneration due to its vascular permeability-inducing and angiogenic properties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection into all retinal layers reaching the retinal pigment epithelium-choroid complex. The actions of ranibizumab result in reduced cell proliferation, reduced formation of new blood vessels, and minimization of vascular leakage. The aim of this study was to evaluate the prospectively macular function in in patients with neovascular age-related macular degeneration (AMD) patients undergoing repeated intravitreal injections of Ranibizumab therapy (Lucentis).

Materials and methods

Twenty patients affected by AMD (age range 60-72 years) were enrolled in the study. Inclusion criteria for this study were: evidence of age-related macular degeneration, angiographic evidence of predominantly classic and occult CNV extending under the center of the foveal avascular zone, absence of coexisting ocular disease. Patients enrolled showed baseline visual acuity ranged 1-0.84 logMAR, central microperimetric (Nikon MP-1) sensitivity 2 to 10 dB. Each patient underwent weekly assessments, for three months, of visual acuity, microperimetry and focal electroretinogram (FERG), performed according to a published technique.

Results

Following the first intravitreal injection, mean visual acuity (Figure 1), microperimetric sensitivity (Figure 2) and FERG amplitude (Figure 3) increased steadily from baseline values over the treatment period, with further improvements following each intravitreal injection (P<0.001).

Figure 1
figure1

Visual acuity (ETDRS)

Figure 2
figure2

Central Microperimetric

Figure 3
figure3

FERG amplitude

Conclusions

Ranibizumab therapy can improve central macular function in patients with predominantly classic and occult CNV.

References

  1. 1.

    Arden GB: Vaegan. Electroretinograms evoked in man by local uniform orpatterned stimulation. J Physiol. 1983, 341: 85-104.

  2. 2.

    Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007, 29 (9): 1850-61. 10.1016/j.clinthera.2007.09.008.

  3. 3.

    McKibbin M, Papastefanou V, Matthews B, Cook H, Downey L: Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye. 2009

Download references

Author information

Correspondence to G C Scalzo.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Scalzo, G.C., Campagna, F., Randazzo, G. et al. Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis). BMC Geriatr 10, A77 (2010) doi:10.1186/1471-2318-10-S1-A77

Download citation

Keywords

  • Vascular Endothelial Growth Factor
  • Visual Acuity
  • Ranibizumab
  • Intravitreal Injection
  • Weekly Assessment